Inside Deal: Henry Fuchs Sold 15,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

November 30, 2016 - By whatsonthorold

Inside Deal: Henry Fuchs Sold 15,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Henry Fuchs Insider Sell

Biomarin Pharmaceutical Inc President – Worldwide R&D and an insider Henry Fuchs lately made a sale of 15,000 company shares having a worth of $1,310,988 at the average share price which was $87.4. Today, Henry Fuchs owns 113,878 shares which are precisely 0.07% of the Company’s market cap.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Out of 16 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 11 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 69% are positive. $175 is the highest target while $99 is the lowest. The $127.93 average target is 47.55% above today’s ($86.7) stock price. BioMarin Pharmaceutical has been the topic of 37 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The rating was initiated by Oppenheimer on Wednesday, November 18 with “Perform”. As per Tuesday, September 1, the company rating was maintained by Wedbush. Barclays Capital downgraded BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, November 29 to “Equal-Weight” rating. As per Wednesday, January 20, the company rating was initiated by Credit Suisse. The firm has “Outperform” rating given on Tuesday, March 22 by Credit Suisse. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Wednesday, August 5. Wedbush has “Hold” rating and $139 price target. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rating on Tuesday, January 19. Wedbush has “Neutral” rating and $117.0 price target. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has “Neutral” rating given on Tuesday, August 25 by Wedbush. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Overweight” rating by Barclays Capital on Friday, August 5. The rating was maintained by SunTrust with “Buy” on Tuesday, August 4.

Insitutional Activity: The institutional sentiment increased to 1.66 in 2016 Q2. Its up 0.38, from 1.28 in 2016Q1. The ratio is positive, as 34 funds sold all BioMarin Pharmaceutical Inc. shares owned while 104 reduced positions. 37 funds bought stakes while 140 increased positions. They now own 153.99 million shares or 5.12% less from 162.30 million shares in 2016Q1.

Temasek Hldgs (Private) Ltd last reported 2.11% of its portfolio in the stock. Platinum Ltd reported 17,220 shares or 0.03% of all its holdings. Fil accumulated 0.12% or 500,962 shares. Mackenzie Corp, a Ontario – Canada-based fund reported 12,138 shares. The New York-based Qci Asset Management has invested 0.01% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Moreover, Frontier Capital Mgmt Limited Company has 0.24% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) for 378,985 shares. Amer Insur Tx last reported 28,095 shares in the company. Services Automobile Association has 29,407 shares for 0.01% of their US portfolio. Credit Suisse Ag holds 550,633 shares or 0.05% of its portfolio. Citigroup Incorporated has 0% invested in the company for 46,821 shares. Tang Capital Mngmt Limited Company reported 90,215 shares or 3.13% of all its holdings. Blackrock Institutional Trust Co Na holds 3.92M shares or 0.05% of its portfolio. Walleye Trading Limited reported 1,104 shares or 0% of all its holdings. Royal London Asset Mgmt Ltd has 0.07% invested in the company for 55,482 shares. Orbimed Advsr Ltd Liability Corp last reported 1.52M shares in the company.

Insider Transactions: Since May 31, 2016, the stock had 0 buys, and 22 sales for $84.09 million net activity. SPIEGELMAN DANIEL K sold $397,320 worth of stock. 139,487 shares were sold by BIENAIME JEAN JACQUES, worth $12.08M on Monday, November 21. Mueller Brian sold $28,700 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, August 1. 15,000 shares were sold by FUCHS HENRY J, worth $1.43 million on Friday, August 26. 5,000 shares were sold by Davis George Eric, worth $452,100. The insider LAWLIS V BRYAN sold $608,064. On Tuesday, September 27 the insider Ajer Jeffrey Robert sold $1.77 million.

The stock decreased 1.88% or $1.66 during the last trading session, hitting $86.7. About 1.12M shares traded hands. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 0.39% since April 26, 2016 and is downtrending. It has underperformed by 5.65% the S&P500.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for various diseases and medical conditions. The company has a market cap of $14.80 billion. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. It currently has negative earnings. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

According to Zacks Investment Research, “BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin’s lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.”

Analysts await BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) to report earnings on February, 23. They expect $-0.40 EPS, up 31.03% or $0.18 from last year’s $-0.58 per share. After $-0.13 actual EPS reported by BioMarin Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts 207.69% negative EPS growth.

More recent BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) news were published by: Nasdaq.com which released: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $––.6 ..” on November 11, 2016. Also Seekingalpha.com published the news titled: “Barclays softens views on five biopharma firms” on November 29, 2016. Nasdaq.com‘s news article titled: “Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $9.8 million ..” with publication date: November 01, 2016 was also an interesting one.

BMRN Company Profile

BioMarin Pharmaceutical Inc. (BioMarin), incorporated on October 25, 1996, develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. The Company’s approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and in other countries. Naglazyme received marketing approval in the United States, the European Union and in other countries. Kuvan was granted marketing approval in the United States and the European Union. Aldurazyme was approved for marketing in the United States, the European Union and in other countries. Firdapse received marketing approval in the European Union.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>